This website uses cookies

This websites contains videos from YouTube. This company uses cookies (third party cookies). If you do not want them to use these cookies, you can indicate so here. However, this does mean that you will not be able to watch videos on this website. We also make use of our own cookies in order to improve our website. We don't share our data with other parties. Which cookies are involved?

This website uses cookies to enable video and to improve the user experience. If you do not want to accept these cookies, indicate so here. Which cookies are involved?

Ga direct naar de inhoud, het hoofdmenu, het servicemenu of het zoekveld.

Back to overview

Karin de Visser group

KarinDeVisser.jpg

Karin de Visser

Group Leader

Personal details

Experience

Throughout my career, I have focused on the intriguing and paradoxical role of the immune system in cancer and metastasis formation. I obtained my Ph.D. in 2002 at the Division of Immunology at the Netherlands Cancer Institute in Amsterdamin the lab of Prof. Dr. Ada Kruisbeek, where I studied the impact of T cell tolerance on tumor-immunotherapy. In 2002, I was awarded a post-doctoral fellowship from the Dutch Cancer Society to pursue my postdoctoral training in the lab of Prof. Dr. Lisa Coussens in the Cancer Research Institute at the University of California, San Francisco. There I developed an active interest in the interplay between adaptive and innate immune system during cancer development. We published one of the first mechanistic reports regarding the pro-tumor functions of B lymphocytes in a mouse model of epithelial carcinogenesis. In 2005 I joined the laboratory of Dr. Jos Jonkers at the Division of Molecular Biology at the Netherlands Cancer Institute, where I expanded my research direction into the field of inflammation and mammary tumorigenesis, using conditional mouse models. Currently I run my own independent research group in the Division of Immunology at the NKI focusing on the role of the innate and adaptive immune system in breast cancer development, metastasis formation and therapy response.

Share this page